Cathelicidin Side Effects: Safety Signals and Warnings
Cathelicidin safety concerns are compound-specific. The main listed side effects are Potential cytotoxicity to host cells at high concentrations, May exacerbate inflammatory skin conditions at supraphysiological levels, and Direct peptide administration can cause injection site inflammation. The main warning signals are Not approved as a therapeutic agent, Excess LL-37 is associated with psoriasis and rosacea pathology, and Synthetic LL-37 is expensive to produce and susceptible to degradation.
Direct Answer
Cathelicidin (LL-37) has solid preclinical data on antimicrobial activity and innate immune modulation, and it is an endogenous human peptide. However, there are no therapeutic clinical trials, systemic delivery is problematic due to rapid degradation, and high concentrations are cytotoxic. Research interest is active but therapeutic translation remains undemonstrated.
- Evidence grade
- Level C
- Research status
- Preclinical
- Category
- Immune Support
- Best for
- Antimicrobial peptide pharmacology, innate immune defense mechanistic research, wound healing models
Reported Side Effects
- Potential cytotoxicity to host cells at high concentrations
- May exacerbate inflammatory skin conditions at supraphysiological levels
- Direct peptide administration can cause injection site inflammation
- Vitamin D-mediated induction is generally safe within recommended ranges
Warnings
- Not approved as a therapeutic agent
- Excess LL-37 is associated with psoriasis and rosacea pathology
- Synthetic LL-37 is expensive to produce and susceptible to degradation
- Systemic administration carries risk of inflammatory side effects
Known or Plausible Interactions
- Vitamin D supplements (upregulate cathelicidin expression)
- Butyrate and other HDAC inhibitors (may enhance CAMP gene expression)
- Antibiotics (potential synergistic or antagonistic interactions depending on class)
Regulatory Context
LL-37 is a research peptide not approved for therapeutic use. Endogenous levels are modulated by vitamin D status. Available from research suppliers. No regulatory approvals for direct clinical application.
Evidence Snapshot
| Evidence grade | Level C |
|---|---|
| Research status | Preclinical |
| Best supported outcomes | Antimicrobial Defense (Level C), Wound Healing (Level C), and Inflammatory Modulation (Level C) |
| Primary citation count | 3 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Cathelicidin Side Effects: Safety Signals and Warnings." Last reviewed 2026-04-04. https://examinepeptides.com/answers/cathelicidin-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.